sub:assertion {
  d:DB05471 v:identifier "DB05471" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05471" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05471> ;
    dv:drugbank-id "DB05471" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dct:description """SGN-30 is an  engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.  SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric ALCL.

SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas."""@en ;
    dct:identifier "drugbank:DB05471" ;
    dct:title "SGN-30"@en ;
    a dv:Drug ;
    rdfs:label "SGN-30 [drugbank:DB05471]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05471> .
}